MissionIR Articles
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appoints Strategic Advisor, Advances Tech Platform as Alternative to Smoking and Vaping
Lexaria Bioscience is dedicated to providing healthful alternatives to drug-substance inhalation by providing an edible technology that works as effectively as smoking or vaping at getting substances into the bloodstream The company’s DehydraTECH platform has…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advances Development of Proprietary Drug-Delivery Platform
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, continues to progress the development and patenting of its DehydraTECH(TM) platform. An article discussing the company reads, “The DehydraTECH(TM) drug-delivery platform can be…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Drug-Delivery Platform May Ease Overdose Risk in Cannabis Edibles
Edible cannabis products are absorbed slowly Consumers of cannabis edibles often mistake the delayed effect for insufficiency, leading to overdosing DehydraTECH drug-delivery platform speeds up absorption, reducing overdose risk Sometimes what is gained on the…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Names New Senior Advisor
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, this morning announced the appointment of Gregg Smith as a Senior Advisor for the company. Smith is the founder of Evolution VC Partners…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Proprietary Drug-Delivery System Featured in Peer-Reviewed Medical Journal
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently announced that results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published in the peer-reviewed…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Stock Jumps After FDA Announcement on Smokeless Tobacco Products
LXRP stock jumped by 24 percent following the FDA’s announcement FDA recently granted the first-ever, modified-risk orders to eight smokeless tobacco products DehydraTECH technology enhances oral delivery of nicotine The recent climb in the stock…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Applauds FDA Forward-Looking Decision on Reduced Risk Tobacco Format
Global innovator in drug delivery platforms Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced that the Food and Drug Administration (“FDA”), for the first time ever, has authorized the marketing of oral nicotine products through…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Platform Offers Alternative to Traditional Inhalation
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative DehydraTECH(TM) platform works to deliver chemical compounds to the bloodstream at speeds similar to inhalation methods, offering an alternative to smoking. An article discussing the company further reads,…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advances Innovation Research Through Agreement with Altria
The program focuses on the pursuit of reduced risk oral nicotine products that make use of Lexaria’s patented DehydraTECH drug delivery platform DehydraTECH has been studied extensively and both human/animal trials confirm its ability to…
-
Predictive Oncology Inc. (NASDAQ: POAI) Inks its Largest Single-Hospital Sale of Revolutionary STREAMWAY(R) System
POAI recently announced the sale of 10 FDA-approved, CE-marked STREAMWAY Systems STREAMWAY Systems are the first truly continuous, direct-to drain fluid-disposal solutions designed specifically for medical applications The announcement is another positive indication that POAI subsidiary…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Featured in Human CBD Study Results Published in Clinical Journal
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, announced that final study results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published (http://ibn.fm/AYzRL) (http://ibn.fm/PfnAA).…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Riding High on Potential Cannabis, Nicotine Uses of Patented Technology
Lexaria Bioscience is helping to revolutionize efforts to provide common drug substances in an ingestible method that avoids unhealthy practices such as inhaled smoking or vaping Lexaria’s DehydraTECH platform works to deliver the chemical compounds…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Provides R&D Program Update
Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today provided an update on the ongoing relationship and pursuit of innovation in oral, reduced risk nicotine consumer products using Lexaria’s patented…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Powdered Formulation of CBD-Rich Hemp Oil Now Available to US Consumers
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently launched its ChrgD+ product, a water-soluble, multispectrum hemp oil in a powdered format powered by the company’s proprietary DehydraTECH(TM) technology for rapid…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Human CBD Study Results Published in Peer Reviewed Clinical Journal
Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announced the publication of final study results of the 2018 human clinical study evaluating CBD delivery and effectiveness using its patented…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Developing Novel Nicotine Ingestion Method as Smoking Alternative
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), an innovative biotechnology company, has set its sights on using its proprietary drug delivery technology to provide an alternative method of nicotine ingestion that is safer than smoking. An…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Positive Findings from Master Collaborative Research Agreement
Biotechnology company and global drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) recently announced the successful completion of its master collaborative research agreement with the National Research Council of Canada (“NRC”) focused…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Ever-Expanding Customer Base for DehydraTECH Drug Delivery Platform
Lexaria Bioscience recently announced its DehydraTECH(TM) patent for pharmaceutical applications of cannabinoids to treat certain disease conditions Lexaria Bioscience’s patented DehydraTECH drug delivery platform can be used to deliver nicotine, cannabinoids and many other useful substances…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Rolls Out Online Sales of Discrete Powdered Formulation of CBD-Rich Hemp Oil
Lexaria Bioscience is an innovator in the field of bioavailable lipophilic active compounds, and it is working to make consumption of certain products through oral ingestion a viable alternative to inhalation A particular focus of…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Conditions
Biotechnology company and global drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announced its receipt of a new patent granted in Australia: #2016367037 / Grant Date August 15, 2019 – “Stable…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial